A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

NCT07001475 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Borderline Personality Disorder
Attention Deficit Hyperactivity Disorder

Interventions

DRUG: BI 3031185
DRUG: Placebo

Sponsor

Boehringer Ingelheim